CRESCITA THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.43 CAD | 0.00% |
|
-1.15% | -12.24% |
| Mar. 13 | Crescita Therapeutics Reports Q4 Net Loss of $0.01 Per Share | MT |
| Mar. 13 | Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023. | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Crescita Therapeutics Inc. is a commercial dermatology company with in-house research and development (R&D) and manufacturing capabilities. It offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. It operates in three segments: Commercial Skincare, Licensing and Royalties and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products for the Canadian and international markets. It also commercializes Pliaglis, NCTF Boost 135 HA, ART FILLER and Obagi Medical in Canada. The Licensing and Royalties segment engaged in licensing the intellectual property related to Pliaglis or its transdermal delivery technologies. Manufacturing and Services segment engaged in the sale of topical products manufactured to client specifications under the Companyâs contract development and manufacturing organization infrastructure, and sales of product development services.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -12.24% | 6.12M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- CTX Stock
- News Crescita Therapeutics Inc.
- Crescita Therapeutics Reports Q3 Revenue of $6 Million; EPS C$0.01; Cash Balance of $10.7 Million
